Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFOXA
- Development stage
- Phase 2
- Lead developer
- Brown University Oncology Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FOLFOXA is a chemotherapy regimen under investigation for locally advanced pancreatic cancer. It combines nab-paclitaxel (Abraxane), oxaliplatin, leucovorin, and 5-fluorouracil (5-FU). Preliminary data suggest that FOLFOXA may offer comparable or superior efficacy to FOLFIRINOX, another common regimen for pancreatic cancer, while potentially being better tolerated. The regimen involves intravenous administration of its components over a 14-day cycle.
- Other names
- FOLFOX-A
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on FOLFOXA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFOXA.